Monopar Therapeutics (MNPR) Interest & Investment Income (2023 - 2025)
Monopar Therapeutics has reported Interest & Investment Income over the past 3 years, most recently at $655473.0 for Q3 2025.
- Interest & Investment Income reached $655473.0 in Q3 2025 per MNPR's latest filing, down from $780769.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $780769.0 in Q2 2025 and bottomed at $73475.0 in Q2 2024.
- Median Interest & Investment Income over the past 3 years was $112260.0 (2023), compared with a mean of $342904.4.
- The largest annual shift saw Interest & Investment Income decreased 11.51% in 2024 before it surged 962.63% in 2025.
- Over 3 years, Interest & Investment Income stood at $112260.0 in 2023, then fell by 11.51% to $99344.0 in 2024, then surged by 559.8% to $655473.0 in 2025.
- Business Quant data shows Interest & Investment Income for MNPR at $655473.0 in Q3 2025, $780769.0 in Q2 2025, and $596845.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 305,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 655,473.00 |
| Jun 30, 2025 | 780,769.00 |
| Mar 31, 2025 | 596,845.00 |
| Sep 30, 2024 | 99,344.00 |
| Jun 30, 2024 | 73,475.00 |
| Mar 31, 2024 | 82,165.00 |
| Sep 30, 2023 | 112,260.00 |